1. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group 
Prof Frédéric Peyrade, MD, Serge Bologna, MD, Vincent Delwail, MD, Prof Jean François Emile, MD, Laurent Pascal, MD, Christophe Fermé, MD, Jean-Marc Schiano, MD, Prof Bertrand Coiffier, MD, Bernadette Corront, MD, Hassan Farhat, MD, Christophe Fruchart, MD, Prof Herve Ghesquieres, MD, Margaret Macro, MD, Prof Hervé Tilly, MD, Bachra Choufi, MD, Richard Delarue, MD, Olivier Fitoussi, MD, Jean Gabarre, MD, Prof Corinne Haioun, MD, Prof Fabrice Jardin, MD 
The Lancet Haematology 
Volume 4, Issue 1, Pages e46-e55 (January 2017)
DOI: /S (16)
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*This patient developed a performance status of 3 after the pre-phase and therefore was not re-assigned to the 3–4 group because they were not considered eligible for conventional chemotherapy by the protocol.
The Lancet Haematology 2017 4, e46-e55DOI: ( /S (16) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Figure 2
Kaplan-Meier plots of overall survival, progression-free survival, and event-free survival
Shaded areas represent 95% CIs.
The Lancet Haematology 2017 4, e46-e55DOI: ( /S (16) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

4. Figure 3
Kaplan-Meier plot of disease-free survival in modified intention-to-treat population
Shaded areas represent 95% CIs.
The Lancet Haematology 2017 4, e46-e55DOI: ( /S (16) )
Copyright © 2017 Elsevier Ltd Terms and Conditions